novo nordisk q2 2025 earnings - Novo Nordisk gains 7% on Q1 beat: is it too late to buy NVO stock?
Novo Nordisk’s rebound got another lift on Wednesday after the Danish drugmaker delivered a first-quarter beat and showed that its new Wegovy pill is gaining traction faster than Wall Street expected.
The NVO stock jumped about 7% in early trading after the results, extending a strong run that has already pushed it well off its March lows.
? KEY STATISTICS
Possession: 55% - 45%
Shots on target: 6 - 3
Pass accuracy: 88% - 82%
Corners: 5 - 2
??? POST-MATCH REACTIONS
"We showed great character," said the winning coach. "The team never gave up."
The losing side rued missed opportunities but vowed to come back stronger.